Merck Seals Acceleron Pharma Deal For $180/Share: Highlights

  • Putting all the speculations at bay, Merck & Co Inc MRK has agreed to acquire Acceleron Pharma Inc XLRN for $180 per share in cash for an approximate total equity value of $11.5 billion.
  • Related Link: Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ.
  • Acceleron's lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH).
  • Sotatercept is in Phase 3 trials as an add-on to the current standard of care for treating PAH.
  • In addition to sotatercept, Acceleron's portfolio includes Reblozyl (luspatercept-aamt), an erythroid maturation recombinant fusion protein approved for anemia in certain rare blood disorders. 
  • Reblozyl is being developed and commercialized through global collaboration with Bristol Myers Squibb & Co BMY.
  • Related: Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia.
  • The transaction is expected to close in Q4 of 2021.
  • Price Action: XLRN stock is up 0.56% at $176.35, MRK shares are up 0.87% at $75.74 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechM&ANewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!